Health Care

Headline News

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb Dividend Announcement

Bristol-Myers Squibb declared a regular quarterly dividend in the amount of $.32 per share payable June 1, 2010 to shareholders of record on May 7, 2010.
At today''s $25.10 stock price the dividend yield is 5.10%.

Mar 5 · 10:03:00 AM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Merck (MRK)

Australia Court Dismisses Claims Against Merck

Today, the Federal Court in Australia dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx.
The Court dismissed all claims against Merck & Co., Inc. specifically finding that Merck was not negligent in its development, scientific study and sale of Vioxx. Merck and MSD Australia disagree with the limited portions of the Court’s findings that were against MSD Australia and intend to appeal them.

Mar 5 · 9:59:00 AM
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Johnson & Johnson (JNJ)

J&J Reaffirms Fiscal 2010 Guidance

Reuters.com is reporting that Johnson & Johnson announced that for fiscal 2010, it continues to expect earnings of $4.85 to $4.95 per share. According to Reuters Estimates, analysts on an average are expecting the Company to report earnings per share (EPS) of $4.92 for fiscal 2010.
At today's stock price of about $63.80, with a 2010 EPS of $4.92 that results in a forward PE of about 13. That seems like a flat out steal of a valuation for J&J.

Mar 5 · 9:55:00 AM · Source: Reuters.com
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Abbott Labs (ABT)

Abbott and GSK Team on Skin Cancer Test

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.
"This is an exciting continuation of our important collaboration with GSK, a leading company in cancer immunotherapy research," said Stafford O'Kelly, head of Abbott's molecular diagnostics business. "The agreement is indicative of our commitment to personalized medicine and our focus on developing innovative companion diagnostic tests that can be used to identify patients most likely to benefit from specific cancer therapies."

Mar 4 · 10:44:00 AM · Source: Reuters.com
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike

Pfizer (PFE)

Pfizer and Medivation Alzheimer's Results

Pfizer and Medivation announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer`s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function.
Dr. David Hung, president and chief executive officer of Medivation, described the results as "unexpected" and said they are "disappointed". That's not good. Pfizer is under a lot of pressure to replace sales from Lipitor, which goes off patent next year.

Mar 4 · 10:41:00 AM · Source: Reuters.com
Track · email · face · Twitter · digg · COMMENTS
by Rich Pike


Previous · Next
Copyright © 2010 MarketBeast.com.
All rights reserved.